MitraClip (mitral clip) is a medical device used to treat mitral valve regurgitation for individuals who should not have open-heart surgery. It is implanted via a tri-axial transcatheter technique and involves suturing together the anterior and posterior mitral valve leaflets. Medical use and indications MitraClip is used for patients with severe secondary mitral valve regurgitation that is refractory to medical therapy. Primary mitral regurgitation is usually due to an organic cause whereas secondary mitral regurgitation is due to a secondary ischemia or cardiomyopathy. Open-heart surgery remains the preferred treatment option when possible for primary mitral regurgitation, due to the effectiveness and long-term record of the procedure in reducing mitral valve regurgitation. Secondary Mitral regurgitation however can have different options in management as surgery has not been proven in clinical trials to be superior The indications for using MitraClip are as follows: Those with symptomatic 3+ or 4+ Chronic Moderate-to-severe or severe Mitral Regurgitation are not candidates for surgery New York Heart Association Functional Class III or IV Favorable anatomy: Mitral Valve area greater than 4.0 centimeter squared, Minimal Calcification/no cleft in grasping area, Flail width less than 15mm, flail gap less than 10mm At least 1+ year of life expectancy Advantages Compared to patients who need open heart surgery, patients who received mitral clip have less need for a blood transfusion and have fewer ventilation days. When compared to the patient who has had open heart surgery, MitraClip was cheaper - approximately $2200 less per person - and the median stay in the hospital post mitral clip is 2.4 days. Contraindications Patients who are unable to receive anticoagulation or dual antiplatelet therapy Active mitral valve endocarditis Mitral valve rheumatic disease Patient that has femoral venous, Inferior vena cava (IVC), intracardiac thrombus Adverse effects and complications The most common complication of transcatheter mitral valve repair is access site bleeding, although transfusion is generally required less often than with surgical mitral valve repair. Rare but serious complications can include infective endocarditis, mitral stenosis, and device embolization. In general, major adverse events in a 30-day post-procedural time period are significantly lower with a transcatheter versus surgical approach. In the EVEREST 2 Clinical Trial, new onset atrial fibrillation and acute kidney failure is higher in MitraClip group when compared to the surgical group Barriers and disadvantages Major obstacles of mitral clip include the novelty of the technology. As of 2016, there were only 75